Evaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic Adenocarcinoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer (NCT05848154) | Shanghai Zhongshan Hospital | 2023-06-01 |
Track Evaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.